Table 2.
Cytogenetics and molecular abnormalities between low and high PLT groups
| Cytogenetics and molecular abnormalities | Low PLT (≤ 65 × 109/L) group (n = 216) | High PLT (> 65 × 109/L) group (n = 114) | P value |
|---|---|---|---|
| Cytogenetics, n (%) | |||
| t(8;21)(q22; q22) | 33 (15.3) | 1 (0.9) | 0.001 |
| inv(16)(p13.1; q22) | 11 (5.1) | 2 (1.8) | 0.138 |
| t(9;11)(p21.3; q23.3) | 0 | 1 (0.9) | 0.745 |
| t(6;9)(p23.3; q34.1) | 1 (0.5) | 1 (0.9) | 1.000 |
| t(v;11q23.3) | 6 (2.8) | 3 (2.6) | 0.938 |
| t(9;22)(q34.1; q11.2) | 1 (0.5) | 0 | 1.000 |
| t(8;16)(p11.2; p13.3) | 0 | 0 | |
| inv(3)(q21.3q26.2) | 0 | 1(0.9) | 0.745 |
| –5, 5q–, − 7, − 17 | 7 (3.2) | 4 (3.5) | 0.897 |
| Complex karyotype | 4 (1.8) | 3 (2.6) | 0.948 |
| Normal cytogenetics | 133 (61.6) | 82 (70.7) | 0.060 |
| Other nondeified cytogenetics | 22 (10.2) | 16 (14.0) | 0.297 |
| Genetic mutations, n (%) | |||
| NPM1 | 29 (13.4) | 21 (18.4) | 0.229 |
| CEBPAbi | 25 (11.6) | 4 (3.5) | 0.013 |
| CEBPAsmbZIP | 10 (4.6) | 6 (5.3) | 0.920 |
| FLT3-ITD | 26 (12.0) | 22 (19.3) | 0.075 |
| TP53 | 1 (0.5) | 1(0.8) | 1.000 |
| ASXL1 | 24 (11.1) | 18 (15.8) | 0.225 |
| RUNX1 | 16 (7.4) | 10 (8.7) | 0.662 |
| EZH2 | 14 (6.5) | 8 (7.0) | 0.853 |
| BCOR | 6 (2.8) | 6 (5.3) | 0.251 |
| SF3B1 | 2 (1.0) | 1 (0.9) | 1.000 |
| SRSF2 | 3 (1.4) | 0 | 0.513 |
| STAG2 | 3 (1.4) | 2 (1.8) | 1.000 |
| U2AF1 | 4 (1.9) | 1 (0.9) | 0.829 |
| ZRSR2 | 1 (0.5) | 0 | 1.000 |
| DNMT3A | 13 (6.0) | 20 (17.5) | 0.001 |
| No mutations detected | 24 (11.1) | 18 (15.7) | 0.225 |
CEBPAbi, biallelic mutations of the CEBPA gene; CEBPAsmbZIP, monoallelic mutations of the CEBPA gene in C-terminal DNA-binding or basic leucine zipper region